Andere Sprachen Theratechnologies Inc.

Aktien

A3ERKM

CA88338H7040

TH

Markt geschlossen - Toronto S.E. Andere Börsenplätze 22:00:00 26.04.2024			% 5 Tage	% 1. Jan.
1,8 ^CAD	0,00 %		-0,55 %	-15,89 %

10.04.	Update zu Theratechnologies; Rückgang um mehr als 5% an der TSX, da sich der Nettoverlust in Q1 verringert und die Entscheidung der FDA abgewartet wird	MT
10.04.	Theratechnologies steigt im US-Vorbörsenhandel um fast 6%, da sich der Nettoverlust in Q1 verringert und die Phase 1-Studie für ein Medikament gegen Eierstockkrebs beschleunigt wird	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders	15.04.
Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference	11.04.
Update On Theratechnologies; Down More Than 5% On TSX As Q1 Net Loss Narrows, Awaits FDA Decision	10.04.
Theratechnologies Up Near 6% In US Premarket As Q1 Net Loss Narrows, Accelerates Phase 1 Trial of Ovarian Cancer Drug	10.04.
Theratechnologies: Fiscal Q1 Earnings Snapshot	10.04.
Theratechnologies Inc. Reports Earnings Results for the First Quarter Ended February 29, 2024	10.04.
Theratechnologies Brief: Citing Acceleration of Phase 1 trial of sudocetaxel zendusortide in advanced ovarian cancer with enrollment of next cohort of patients underway at higher dose level	10.04.
Theratechnologies Brief: FY2024 revenue guidance confirmed between US$87-$90 million and an Adjusted EBITDA in the range of $13-15 million	10.04.
Theratechnologies Brief: Q1 2024 consolidated revenue of US$16.2 Million; Says Report marks third consecutive quarter of near-flat-to-positive Adjusted EBITDA	10.04.
Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024	10.04.
Theratechnologies Inc. Re-Affirms Earnings Guidance for the Fiscal Year 2024	10.04.
North American Morning Briefing : Traders Await -2-	10.04.
Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform	08.04.
Theratechnologies Inc. Preclinical Data Presentation At AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology? Oncology Platform	08.04.
Theratechnologies Appoints Elina Tea to its Board of Directors	05.04.
Theratechnologies Inc. Appoints Elina Tea to its Board of Directors and as Member of the Company's Audit Committee	05.04.
Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update	03.04.
Theratechnologies To Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology Platform	28.03.
Theratechnologies Brief: To Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology Platform	28.03.
Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ Platform	28.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Theratechnologies Inc.

Aktien

A3ERKM

CA88338H7040

TH

Andere Sprachen

Filter